AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02895178 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Combined aerobic and strength exercise training
Description: Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
Study NCT02942888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide riboside
Description: Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
Study NCT02942888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
Study NCT02942888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Pill
Description: This is a placebo compounded by ChromaDex, Inc.
Study NCT02942888 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar Pill
Description: This is a placebo compounded by ChromaDex, Inc.
Study NCT03033680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]PBR06
Description: PET radiopharmaceutical
Study NCT02678962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SN6AD1
Description: Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
Study NCT02678962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SBL-3
Description: Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
Study NCT02678962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LS-313 MF30
Description: Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
Study NCT02678962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AT LISA tri 839 MP
Description: Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
Study NCT02678962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: Bilateral cataract surgery with implantation of ART toric multifocal IOLs
Study NCT02678962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LS-313 MF30T
Description: Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
Study NCT00988156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eslicarbazepine acetate (BIA 2-093)
Description: Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~The recommended target dose of double-blind study treatment will be 20mg/kg/day.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year.
Study NCT00988156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eslicarbazepine acetate
Description: Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.~Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year.
Study NCT00742846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 5ml 1% Lidocaine alone into the shoulder joint.~intra-articular local anesthetic injection
Study NCT00742846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 5ml 1% Lidocaine alone into the subacromial space.~subacromial local anesthetic injection
Study NCT03810547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 10 Mg/mL Intravenous Emulsion
Description: when spinal anesthesia is not satisfactory intervention drugs are used
Study NCT03774771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Capsule for oral administration
Study NCT03774771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules for oral administration
Study NCT03724279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ByCross Atherectomy and Thrombectomy
Description: After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening.
Study NCT02315040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVIE
Description: EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
Study NCT02315040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intrauterine Insemination
Description: standard intrauterine insemination procedure
Study NCT01393210 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low calorie diet plus beta-glucan
Description: beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
Study NCT01393210 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-calorie diet
Description: low-calorie diet only for 12 weeks.
Study NCT00887159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT00887159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00887159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT00887159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT00887159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT00887159 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00887159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00887159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT00483678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Study NCT00483678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Study NCT00483678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Study NCT00483678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care
Study NCT00483678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Study NCT03344783 — intervention group
Intervention type: OTHER
Intervention: PUFA and R-TFA
Description: PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography
Study NCT02915627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Antishock garment
Description: anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
Study NCT04068077 — intervention group
Intervention type: DEVICE
Intervention: ApolloVue™ S100 image system, Viper1-S003
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
Study NCT03268408 — intervention group
Intervention type: BEHAVIORAL
Intervention: Baby Newsletter
Description: eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
Study NCT02479204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-334441 2 mg
Description: capsule containing ACT-334441 at a strength of 2 mg
Study NCT05235555 — intervention group
Intervention type: DEVICE
Intervention: Transcatheter heart valve (THV) with CE approval
Description: TAVI trough femoral access or alternative routes
Study NCT02479204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-334441 4 mg
Description: capsule containing ACT-334441 at a strength of 4 mg
Study NCT02479204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ACT-33441-matching placebo
Study NCT02479204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: film-coated tablet containing atenolol at a strength of 50 mg
Study NCT02479204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem ER
Description: film-coated tablet containing diltiazem at a strength of of 120 mg
Study NCT00045630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT02334072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask classical application
Description: Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
Study NCT02334072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel laryngeal mask application
Description: I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
Study NCT02334072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobra laryngeal mask application
Description: Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
Study NCT02334072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme laryngeal mask application
Description: Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
Study NCT02334072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proseal laryngeal mask application
Description: Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
Study NCT02554799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 formulation A
Description: MMV390048 formulation A, tablet
Study NCT02554799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 formulation B
Description: MMV390048 formulation B, tablet
Study NCT00045630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study NCT00045630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00045630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT03471104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAID in clinical diabetes consultations
Description: The intervention starts when participants complete PROMs before an annual consultation. The physician reviews the PAID (problem areas in diabetes scale) scores with the participant. Participants with one or more single PAID item(s) scored 3 or 4, or a PAID score ≥30, will be referred to extra follow-up which will consist of at least two diabetes nurse consultations. The nurses will follow a communication manual based on key elements from empowerment theory and self-determination theory.~The participants then complete the PROMs prior to the next annual consultation with the physician.
Study NCT04721938 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Systematic weight loss intervention
Description: Weight reduction through life style changes in diet and exercise by the following means:~* Counselling with a Nutritionist Nurse on diet and exercise~* Online Smartphone coaching program (Life-sum App)~* Motivational and adjustment dialogue and counselling with Nutritionist Nurse including anthropometric measures every month
Study NCT04047368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotablation
Description: Percutaneous Coronary Intervention using Rotablation
Study NCT04047368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Lithoplasty
Description: Percutaneous Coronary Intervention using Lithoplasty
Study NCT02786212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02786212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT01448889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% oxigen
Description: patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Study NCT01448889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Study NCT03773666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
Study NCT03300219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance
Description: CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
Study NCT03773666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
Study NCT04172350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCareBreast
Description: The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.
Study NCT04172350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
Study NCT04172350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
Study NCT03183063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4DCT and SPECT/CT
Description: Each patient will receive two 4DCT followed by SPECT/CT.
Study NCT03183063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4DCT with BiPAP and SPECT/CT
Description: Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT
Study NCT03183063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4DCT with CTA in suspected PE
Description: Each patient will receive 4DCT before or after CTA for suspected PE
Study NCT01805687 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Zileuton extended release
Study NCT02330354 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Me, Healthy We
Description: The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
Study NCT02330354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Me, Healthy We
Description: The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
Study NCT03765216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L Polyethylene Glycol (PEG)
Description: Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
Study NCT03765216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L Polyethylene Glycol (PEG)
Description: Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen
Study NCT03765216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4L Polyethylene Glycol (PEG)
Description: High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
Study NCT00078806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered by subcutaneous injection twice a week
Study NCT00078806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection twice a week
Study NCT03190135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOKS: 2 day a week before-school physical activity program
Description: Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
Study NCT03561519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Fecal suspension administered in colonoscopy into the cecum of the patient.
Study NCT03561519 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As a placebo a fecal suspension made of patients own feces is administered into the cecum of the patient in colonoscopy.
Study NCT02567656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP6530
Description: Tablet starting at 200 mg
Study NCT00920738 — intervention group
Intervention type: OTHER
Intervention: metabolic assessment
Description: Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
Study NCT03190135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOKS: 3 day a week before-school physical activity program
Description: Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
Study NCT03394742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: Peer support persons are breast cancer survivors, who were educated to give peer support. They contacted participants by telephone.
Study NCT03870464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT-scans extended
Description: CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.
Study NCT03870464 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan of the brain
Description: MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.
Study NCT03870464 — intervention group
Intervention type: OTHER
Intervention: Prospective registration of irAEs
Description: irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.
Study NCT03870464 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life questionnaires
Description: Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
Study NCT00286624 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Islets of Langerhans
Description: Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.